Two approvals in a week for drugs made at Ranbaxy’s New Jersey OHM Laboratories subsidiary have eased the generics firm’s North American regulatory woes and strengthened its position in the expanding US market.
The FDA says that Sandoz, the generics arm of Swiss drug major Novartis, failed to validate manufacturing processes used to produce metoprolol succinate ER tablets at its plant in Wilson, North Carolina.
Eli Lilly has again teamed up with Indian research firm Suven Life
Sciences in a deal that will focus on preclinical research of
molecules in the therapeutic area of central nervous system (CNS)
As Speedel's fourth renin inhibitor enters clinical trials, this
award-winning new class of drugs has generally been well-received.
However, some have raised questions about their safety and
Several groups of scientists are developing compounds that slowly
release carbon monoxide directly into the bloodstream and that
could be used to treat diseases as diverse as high blood pressure,
heart disease and cancer.
Actelion has announced it is acquiring biopharmaceutical company
CoTherix for $420m (€328m) with the objective of taking over and
increasing the distribution of Ventavis, the only approved inhaled
therapy for the treatment of Pulmonary...
The PiperJaffray conference gave biopharmaceutical company Speedel
ample opportunity to inform investors of its intentions for 2006
and beyond. The company have just released promising data on a new
first-in-class diabetic treatment.
BioPharmaceutical company Protherics, were on hand at the
PiperJaffray conference providing pipeline and company updates to a
audience of investors and analysts. The company are coming off the
back of a successful deal with Astrazeneca...
NicOx and Merck have signed an agreement to collaborate on the
development of new antihypertensive drugs. The agreement follows
the successful completion of the companies' research collaboration,
which has generated promising...
Swiss drugs firm Novartis are claiming success in its latest
treatment for hypertension. Aliskiren - the first in a new class of
antihypertensive drugs has shown to be effective as a single
treatment for patients with high blood pressure.
A study showing that drugs distributed in blister packages rather
than in bottles increase the likelihood that medications will be
taken properly, could help encourage the take-up of unit-dose
packaging in the US market, reports Phil...
According to a new report diabetic nephropathy represents a
multi-billion-dollar market that is poorly served by existing
drugs. All this is set to change as Palosuran, currently in
clinical development, could become the first drug...
Swiss drugmaker Novartis says that its renin inhibitor drug
aliskiren (SPP100), which potentially represents the first in a new
class of orally-active drugs for high blood pressure, has shown
promising data in a clinical trial.
Speedel Experimenta has announced the completion of its human
micro-dosing studies into renin inhibitors that are set to provide
an effective means of treating hypertension and for protecting end
organs such as the heart and kidneys.
The US Food and Drug Administration (FDA) has created a new rule
requiring content and warning labelling for over-the-counter (OTC)
drugs that contain levels of calcium, magnesium, sodium, or
potassium that might be harmful to people...
Earlier this week, the US Food and Drug Administration suspended
the approval of a generic version of Pfizer's high blood pressure
drug Norvasc (amlodipine besylate) developed by India's Dr Reddy's